OPC Pharmaceutical Joint Stock Company has announced its plan for 2025, expecting consolidated revenue of 1.24 trillion VND, a 28% increase from 2024, and pre-tax profit growth of 29% to 177 billion VND. The company aims to develop standard raw material areas and build an extraction factory to enhance product quality. The Vietnamese pharmaceutical market continues to grow steadily at an average rate of 8-10% per year. Although new tax policies from the US may indirectly affect the pharmaceutical sector, OPC can capitalize on the opportunity to localize raw materials and reduce dependence on imports. OPC is also exploring export markets such as China and South Korea while owning several GACP-WHO certified medicinal herb growing areas. In 2024, the company reported revenue of 969.5 billion VND and a post-tax profit of nearly 110 billion VND.
Leave a Reply